Explosive Growth in the Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market
The global non-alcoholic steatohepatitis treatment market is witnessing explosive growth, valued at USD 7.70 billion in 2024 and projected to reach USD 55.52 billion by 2032, registering a staggering CAGR of 28.05% from 2025 to 2032. This unprecedented expansion is primarily fueled by the rising global prevalence of obesity, type 2 diabetes, hypertension, and metabolic syndrome—conditions that significantly elevate the risk of NASH and non-alcoholic fatty liver disease (NAFLD).
Market Dynamics & Growth Catalysts
Non-alcoholic steatohepatitis (NASH), a progressive liver disease characterized by inflammation and fibrosis, has emerged as a silent epidemic in recent years. Its strong correlation with metabolic risk factors like obesity and diabetes is transforming the way global healthcare systems approach liver-related disorders.
Get Ahead of Market Shifts: Request Your Sample Report!
According to the Centers for Disease Control and Prevention (CDC):
40.3% of U.S. adults are obese in 2024
38 million Americans live with diabetes, 90–95% of whom have type 2 diabetes
116 million adults in the U.S. suffer from hypertension
The U.S. reported 17.5 million prevalent NASH cases in 2024, expected to rise to 23.33 million by 2030. These alarming numbers are creating an urgent demand for advanced NASH therapeutics.
Additional drivers include:
Breakthroughs in drug discovery
Rising patient awareness
Regulatory incentives
Accelerated biopharma investments
Key Regional Insights
North America: Market Leader with 78% Share in 2024
North America, especially the United States, commands a dominant share of the NASH treatment market due to:
High burden of metabolic diseases
Advanced R&D capabilities in biopharma
Swift FDA approvals and ongoing clinical trials
Madrigal Pharmaceuticals and Novo Nordisk are pioneering liver-specific NASH drug development. Madrigal notably achieved FDA approval for a groundbreaking NASH drug, spurring momentum in early intervention and personalized therapies.
Asia-Pacific: Fastest-Growing Region with 30.2% CAGR
Asia-Pacific, driven by China and India, is emerging as a powerful growth region:
China may become the global NAFLD/NASH epicenter with 314.5 million projected NAFLD cases by 2030
Its population of 402 million aged 60+ by 2040 will exacerbate liver disease vulnerability
India is gaining momentum as a biotech hub:
In April 2024, Apollo Hospitals launched a Fatty Liver Clinic in Chennai
Emphasis is growing on preventive care, advanced diagnostics, and specialized treatments
Drive Your Business Forward: Enquiry the Report!
Europe: Focus on Cost-Efficiency and Public Health
Europe’s growth is underpinned by:
Aging populations
Sedentary lifestyles and increasing obesity
Rising need for affordable, accessible treatment options
Germany is leading in adoption of therapies like Lanifibranor and Obeticholic Acid (OCA). Healthcare systems are being pushed to act due to increasing hospitalizations and rising economic burden.
According to a 2020 study by the National Library of Medicine (NLM):
Annual direct medical costs per NASH patient in Europe range between USD 402 and USD 1,321
These financial pressures are steering the market toward cost-efficient therapies
Industry Landscape & Competitive Outlook
Leading Players in the NASH Treatment Market:
Madrigal Pharmaceuticals Inc.
Novo Nordisk A/S
Intercept Pharmaceuticals, Inc.
Galmed Pharmaceuticals Ltd
Inventiva
Galectin Therapeutics Inc.
NGM Biopharmaceuticals, Inc.
AbbVie Inc.
Gilead Sciences, Inc.
Bristol-Myers Squibb Company
Recent Development Highlight
In August 2024, Shilpa Medicare experienced an 11% stock surge after successful Phase 3 trials for SMLNUD07 (NorUDCA)—a novel drug targeting NAFLD. This development addresses a major treatment gap in early-stage fatty liver diseases and could catalyze widespread adoption of new therapies for NASH.
Market Segmentation
By Drug Type:
Vitamin E and Pioglitazone
Obeticholic Acid (OCA)
Resmetirom
Lanifibranor
Semaglutide
Cenicriviroc
Aramchol
Other Drugs
By Disease Stage:
NASH Stage F0
NASH Stage F1
NASH Stage F2
NASH Stage F3
NASH Stage F4
By Distribution Channel:
Retail and Specialty Pharmacies
Hospital Pharmacies
Other Pharmacies
Conclusion
As NASH evolves from a silent disease to a global public health priority, the treatment landscape is undergoing a massive transformation. The confluence of rising disease incidence, proactive regulatory frameworks, and pharmaceutical innovation is paving the way for a high-growth decade.
Key Takeaway: Stakeholders across the healthcare ecosystem—providers, policymakers, and pharma companies—must work in concert to ensure early diagnosis, affordable treatment access, and timely intervention as the fight against NASH intensifies.
Explore SNS Insider Related Ongoing Coverage on Healthcare Market Insights Domain:
About SNS Insider
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Mail us: [email protected]
